S
Sandip Pravin Patel
Researcher at University of California, San Diego
Publications - 158
Citations - 9557
Sandip Pravin Patel is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 30, co-authored 117 publications receiving 5767 citations. Previous affiliations of Sandip Pravin Patel include University of Texas MD Anderson Cancer Center & Duke University.
Papers
More filters
Journal ArticleDOI
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
TL;DR: Improved understanding of the host immune system and tumor microenvironment will better elucidate which patients derive benefit from these promising agents, and the issue of PD-L1 as an exclusionary predictive biomarker is clarified.
Journal ArticleDOI
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M. Goodman,Shumei Kato,Lyudmila Bazhenova,Sandip Pravin Patel,Garrett M. Frampton,Vincent A. Miller,Philip J. Stephens,Gregory A. Daniels,Razelle Kurzrock +8 more
TL;DR: Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse cancers treated with various immunotherapies, and Benefit from dual checkpoint blockade did not show a similarly strong dependence on TMB.
Journal ArticleDOI
Microbiome analyses of blood and tissues suggest cancer diagnostic approach
Gregory D. Poore,Evguenia Kopylova,Qiyun Zhu,Carolina S. Carpenter,Serena Fraraccio,Stephen Wandro,Tomasz Kosciolek,Tomasz Kosciolek,Stefan Janssen,Stefan Janssen,Jessica L. Metcalf,Se Jin Song,Jad N. Kanbar,Sandrine Miller-Montgomery,Robert K. Heaton,Rana R. McKay,Sandip Pravin Patel,Austin D. Swafford,Rob Knight +18 more
TL;DR: Microbial nucleic acids are detected in samples of tissues and blood from more than 10,000 patients with cancer, and machine learning is used to show that these can be used to discriminate between and among different types of cancer, suggesting a new microbiome-based diagnostic approach.
Journal ArticleDOI
Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines
David S. Ettinger,Douglas E. Wood,Charu Aggarwal,Dara L. Aisner,Wallace Akerley,Jessica Bauman,Ankit Bharat,Debora S. Bruno,Joe Y. Chang,Lucian R. Chirieac,Thomas A. D'Amico,Thomas J. Dilling,Michael C. Dobelbower,Scott N. Gettinger,Ramaswamy Govindan,Matthew A. Gubens,Mark Hennon,Leora Horn,Rudy P. Lackner,Michael Lanuti,Ticiana A. Leal,Jules Lin,Billy W. Loo,Renato Martins,Gregory A. Otterson,Sandip Pravin Patel,Karen L. Reckamp,Gregory J. Riely,Steven E. Schild,Theresa A. Shapiro,James P. Stevenson,Scott J. Swanson,Kurt Tauer,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +35 more
TL;DR: The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) as discussed by the authors address all aspects of management for NSCLC, focusing on recent updates in immunotherapy.
Journal ArticleDOI
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
David S. Ettinger,Dara L. Aisner,Douglas E. Wood,Wallace Akerley,Jessica Bauman,Joe Y. Chang,Lucian R. Chirieac,Thomas A. D'Amico,Thomas J. Dilling,Michael C. Dobelbower,Ramaswamy Govindan,Matthew A. Gubens,Mark Hennon,Leora Horn,Rudy P. Lackner,Michael Lanuti,Ticiana A. Leal,Rogerio Lilenbaum,Jules Lin,Billy W. Loo,Renato G. Martins,Gregory A. Otterson,Sandip Pravin Patel,Karen L. Reckamp,Gregory J. Riely,Steven E. Schild,Theresa A. Shapiro,James P. Stevenson,Scott J. Swanson,Kurt Tauer,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +32 more
TL;DR: The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC and for the 2018 update, a new section on biomarkers was added.